Medical compositions containing ghrelin
It is provided a pharmaceutical composition stably containing ghrelin or its derivative, which is an endogenous growth hormone secretagogue (GHS) to a growth hormone secretagogue-receptor (GHS-R), comprising a aqueous solution containing the ghrelins having pH range of 2 to 7, wherein the aqueous solution having pH range of 2 to 7 is a buffer solution, especially, glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer or phthalate buffer, and the concentration of the ghrelins in the solution is from 0.03 nmol/mL to 6 μmol/mL.
1. A pharmaceutical composition comprising stable, physiologically-active ghrelin or its derivative in an aqueous solution which dissolves said ghrelin, and further comprising a pH adjuster,
wherein:
said aqueous solution has an acidic pH ranging from 3 to 6 to prevent the degradation of a hydrophobic group on the side chain of the serine or theronine at the third residue of said ghrelin,
the pH adjuster comprises hydrochloric acid, sulfuric acid, nitric acid, boric acid, carbonic acid, bicarbonic acid, gluconic acid, sodium hydroxide, potassium hydroxide, aqueous ammonia, citric acid, monoethanolamine, lactic acid, acetic acid, succinic acid, fumaric acid, maleic acid, phosphoric acid, methanesulfonic acid, malic acid, propionic acid, trifluoroacetic acid, a salt thereof, or mixtures of said pH adjusters, and
said composition is suitable for pharmaceutical administration to a human.
2. The pharmaceutical composition of claim 1 , further comprising a buffer agent.
3. The pharmaceutical composition of claim 2 , wherein the buffer agent comprises glycine, acetic acid, citric acid, boric acid, phthalic acid, phosphoric acid, succinic acid, lactic acid, tartaric acid, carbonic acid, hydrochloric acid, sodium hydroxide, the salt thereof, or mixtures of said buffer agents.
4. The pharmaceutical composition of claim 2 , wherein the concentration of the buffer agent in the solution ranges from 0.01 mM to 1000 mM.
5. The pharmaceutical composition of claim 1 , wherein the solution comprises a buffer solution.
6. The pharmaceutical composition of claim 5 , wherein the buffer solution comprises glycine hydrochloride buffer, acetate buffer, citrate buffer, lactate buffer, phosphate buffer, citric acid-phosphate buffer, phosphate-acetate-borate buffer, phthalate buffer, or a mixture of said buffer solutions.
7. The pharmaceutical composition of claim 1 , wherein the concentration of ghrelin in the solution ranges from 0.03 nmol/mL to 6 μmol/mL.
8. The pharmaceutical composition of claim 1 , wherein the ghrelin is in the form of an acetic acid salt.
9. The pharmaceutical composition of claim 1 , wherein the ghrelin comprises human ghrelin.
10. The pharmaceutical composition of claim 1 , further comprising an anti-adsorbent.
11. The pharmaceutical composition of claim 10 , wherein the concentration of the anti-adsorbent ranges from 0.001% to 5%.
12. The pharmaceutical composition of claim 10 , wherein the anti-adsorbent comprises a surfactant.
13. The pharmaceutical composition comprising the ghrelin of claim 1 in the form of a dried powder obtained from a solution.
14. The pharmaceutical composition of claim 13 , wherein the powder comprises a lyophilized powder.
15. The pharmaceutical composition of claim 1 , wherein said physiologically-active ghrelin or its derivative is present in an amount effective to adjust the secretion of a growth hormone.